Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-29

FDA Approved: PIFELTRO — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for PIFELTRO (doravirine) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PIFELTRO (doravirine)

Snippet

SUPPL AP for PIFELTRO (DORAVIRINE)